Shaun A. Kirkpatrick

Kirkpatrick has more than 14 years experience managing venture investments and technology development programs in the fields of cancer, inflammation, metabolic disease and neurological disorders, and technology platforms related to biotherapeutics and antibodies. He oversees RCT's BioVentures investments, technology development programs and special licensing programs in North America, Europe and Australia. He is a member of the board of directors for several start-up biomedical companies and ventures. Kirkpatrick is also a member of the operations board for the Critical Path Institute, an institute formed with the U.S. Food and Drug Administration, SRI International and The University of Arizona to accelerate the development of safe human therapeutics.

Professional Experience

Research Corporation Technologies
President & Chief Executive Officer, June 2005–present
President & Chief Operating Officer, 2004–May 2005
Vice President & Managing Director, 2001–2004
Director, Commercialization, 1999–2000
Venture Development Associate, 1993–1999

Board Membership

Flinn Foundation
Board of Directors, 2008–present

University of Arizona College of Pharmacy
National Advisory Board, 2005–present

The Critical Path Institute
Operating board member, 2005–present

Cylene Pharmaceuticals Inc.
Director, 2005–present

Sertoli Technologies Inc.
Chairman, 1996–present

Past Board Membership

Alimmune LLC
Director, 2001–2007

APT Pharmaceuticals Inc.
Director, 2005–2007

Imagine Pharmaceuticals Inc.
Director, 2005

Prolifia Inc.
President and Chairman, 2000–2004

Therapeutic Human Polyclonals Inc.
Chairman, 2000–2007

Education

Johns Hopkins University School of Advanced International Studies

M.A., International Economics and Science/Technology in International Relations

The University of Arizona

B.A., Biology and Economics

Contact

skirkpatrick@rctech.com
Rebecca Buescher, Asst. to the President and CEO
Jennie Watkin, Sr. Secretary